Deadly cure: The role of cough syrups in the deaths of dozens of children
At least 20 children in India have died after consuming cough syrups contaminated with diethylene glycol, raising safety concerns
Nawab Khan pulls a donkey cart through the narrow lanes in Churu, Rajasthan. On October 2, he took his six-year-old son Anas to the district hospital. The boy had a cough and cold – the kind of illness every parent deals with when the season changes.
Doctors administered the boy dextromethorphan hydrobromide syrup, a generic cough syrup supplied at government hospitals in Sikar and Bharatpur under Chief Minister’s free medicine scheme.
Two days later, Anas’s condition had worsened. The doctors referred him to JK Lon Hospital in Jaipur, 200 kilometers away. He reached the state’s largest children’s hospital at 4 am on October 4. At 10 am, Anas was dead.
The family alleges the cough syrup killed their son. It was not the only death in the state that has been reportedly linked to the medicine. The Rajasthan government has ordered an inquiry and banned dextromethorphan hydrobromide syrup and all 19 of its formulations. Drug Controller Rajaram Sharma has been suspended.
In neighboring Madhya Pradesh, 19 children aged one to six died within weeks of taking a common cough syrup. Health authorities tested water supplies for mosquito-borne diseases, examined food sources. But it was a government laboratory in Chennai, southern state of Tamil Nadu, that provided the answer: the syrup administered to children contained 48.6% diethylene glycol.
Following the Madhya Pradesh deaths, the authorities issued alertsfor two additional cough syrup brands: Respifresh (manufactured by Rednex Pharmaceuticals) and RELIFE (manufactured by Shape Pharma). Both contained diethylene glycol several folds above the permissible limit.
Diethylene glycol is an industrial solvent – used in antifreeze and brake fluid – and is toxic to humans. When ingested, it metabolizes into acidic compounds that crystallize in the kidneys, causing acute kidney injury. Children are particularly vulnerable because of their smaller body mass – a dose that might sicken an adult can kill a child.
The WHO maintains a database of diethylene glycol contamination incidents in medicines worldwide, documenting mass poisoning events across multiple countries. The compound has no legitimate use in pharmaceuticals. Its presence indicates either deliberate substitution – replacing expensive pharmaceutical-grade glycerin with cheap industrial diethylene glycol – or complete collapse of quality control systems that should catch such contamination.
The contaminated product that allegedly lead to deaths in Madhya Pradesh was Coldrif syrup, manufactured by Sresan Pharmaceuticals in Tamil Nadu. By October 2, tests had confirmed the contamination and the medicine was banned. Madhya Pradesh police arrested G. Ranganathan, the company’s owner, in Chennai. He faces manslaughter charges. On October 13, The Tamil Nadu Drugs Control Department canceled all manufacturing licenses of Sresan Pharmaceuticals and closed the company.
The same day, the World Health Organization (WHO) issued a health advisory warning against the use and distribution of cough syrups believed to be responsible for the children’s deaths. WHO’s notification mentioned all three medicines reflagged by Indian authorities: specific batches of COLDRIF, Respifresh TR and ReLife, manufactured by Sresan Pharmaceutical, Rednex Pharmaceuticals, and Shape Pharma.
Meanwhile, the Indian Health Ministry announced inspections at 19 other manufacturing units across six states of the country. The scale of the crackdown suggests authorities suspect the contamination problem extends beyond the three identified companies.
Painful history
Recent death across Indian states may come as a shock to families but not as a surprise to the authorities.
Between December 2019 and January 2020, at least 12 children under five died in Jammu, Indian-administered Kashmir, allegedly after consuming cough syrup. Child safety activists stated the actual toll was likely higher.
The Indian government took strict actions to increase oversight of the manufacture of the medicine. New Delhi introduced mandatory additional testing for exported cough syrups at government laboratories. Medicines sold domestically face no such requirement.
“Indian law requires drugmakers to test each batch of raw materials and final products using the Indian pharmacopeia,” senior drug inspector Vaibhav Babbar told RT over the phone. In 2023, Babbar was instrumental in shutting down several cough syrup manufacturing sites where contamination of industrial grade of diethylene glycol (DEG) was found. In one of those cases, Noida-based Marion Biotech was exporting contaminated medicines to Uzbekistan, which allegedly resulted in the deaths of 18 children in the country.
The WHO’s latest notification stated that, according to India's Central Drugs Standard Control Organization (CDSCO), none of the contaminated medicines identified following the recent cases had been exported from India and there is currently no evidence of illegal export. The global body, however, encouraged national regulators to pay attention to “informal and unregulated supply chains where products may circulate undetected.”
In a written advisory from October 7, India's drugs controller general, Rajeev Raghuvanshi, stated that factory inspections revealed that drug makers had failed to test each batch of medicinal ingredients as legally mandated by law.
“It has been observed that manufacturers are not carrying out testing of each batch for verification of compliance with the prescribed standards before using them in manufacture and also in finished products,” the regulator said.
According to experts, this casts a shadow on India’s position as one of the world’s key medicine exporters. India supplies 40% of the generic medicines used in the US and over 90% of all medicines to many African nations. The country’s pharmaceutical industry is valued at $50 billion, making it the third largest globally, after the US and China.
India’s pharmaceutical exports exceed $25 billion annually. It produces one-third of the world’s vaccines. Indian generic medicines make life-saving drugs affordable in developing countries. When health systems in Africa faced medicine shortages during Covid-19, they turned to Indian manufacturers.
However, after the deaths in Uzbekistan and Gambia, several African nations increased scrutiny of Indian pharmaceutical imports.
Ayushmann Kumar, a resident of Gurgaon in Haryana who exports medicine and other supplies to gulf countries, suggested in a telephonic conversation with RT that there is increased scrutiny of Indian medicines.
“The Indian pharma industry has lost of a bit of trust in the international market and this is for the smaller companies which used to provide drugs at good rates and were very effective earlier,” he said. “We have dropped many such companies and now exporting the medicines which have a clean record. One of my orders to the tune of 2.5 million got canceled due to the recent episode.”
For India, however, the details emerging from Rajasthan and Madhya Pradesh reveal how contaminated medicine can potentially enter government medicines and vaccines distribution systems that are particularly essential for vulnerable section of the population.
Kayson Pharma, the company whose cough syrup has been linked to the tragedy in Rajasthan, had come to the attention of the government long before the deaths. The company supplied dextromethorphan hydrobromide syrup under the state’s Chief Minister’s Free Medicine Scheme.
In February 2025, six months before Anas died, a Kaysons syrup batch failed testing. The state banned the product for one year. “This wasn’t Kaysons’ first failure. Between 2021 and 2023, 40 samples from the company reportedly failed quality tests across 10 Rajasthan districts,” a senior drug office bearer at Rajasthan’s drug regulatory office told RT on the condition of anonymity.
The company faced a 19-month ban. When the ban ended, Kaysons was not blacklisted and allegedly resumed supplying medicines to government hospitals and clinics. “It is very unfortunate that we have to see children dying allegedly due to adulterated medicines when medicines are meant to save lives,” the official said.
Questionable drug
India’s cough syrup market is projected to grow from $262.5 million in 2024 to $743 million by 2035, according to Market Research Future. This is despite the WHO advising against the use of cough and cold medicines for children at all.
An acclaimed pediatrician in Mumbai, who spoke to RT on condition of anonymity, explained that most persistent coughs in Indian children result from allergies and airway irritation caused by pollution, not infections. “I don’t usually prescribe cough syrups for ordinary coughs and colds – except occasionally for comfort,” he said. “If a child is coughing badly and can’t sleep, I may give a dose of a mild syrup just to ease the discomfort. The main goal is relief, not treatment.”
Most childhood coughs are viral and abate within a week without medication. Medical literature shows no evidence that cough syrups shorten illness duration. The pediatrician noted that recurrent wet coughs – common in polluted cities – respond best to bronchodilators delivered through inhalers or nebulizers, not oral syrups.
Yet syrups remain the default treatment across India, particularly in rural areas where up to 75% of primary care visits are handled by informal providers without medical degrees.
Dr. Kafeel Khan, who worked as a pediatrician in Gorakhapur, Uttar Pradesh, recalled “syrups being handed out everywhere – even by those with no degree.”
Dr. Khan described another dynamic: “If a child’s cough or cold doesn’t improve in a couple of days, they often consult another doctor who will give a cough syrup.” He has observed qualified pediatricians prescribe ambroxol syrup to children under two, despite the fact that toddlers cannot expel the loosened mucus, creating aspiration pneumonia risk.
The Madhya Pradesh doctor who prescribed the contaminated syrup linked to recent deaths defended himself by stating: “I’ve been prescribing this cough syrup for 15 years.”
Nawab Khan continues pulling his donkey cart through Churu’s lanes. His son is buried. The grieving father, meanwhile, is worried that the next contaminated batch of the same medicines may already be in production. “The next child may already be taking it. The next family may already be traveling to a distant hospital like I did, hoping for treatment that will arrive too late.”
In a written reply in a messenger, the Rajasthan government official told RT the actual cause of deaths is under investigation and primary evidence “suggest the role of adulterated cough syrups.”“This is a very sensitive matter and we have not reached any conclusion yet. We condemn the deaths and will ensure no life is lost due to medicines,” the official said.
We use cookies and similar technologies to enhance your experience, analyze site traffic, personalize content, and ensure the security of our platform. By clicking "Accept All", you consent to our use of cookies.
